{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:44:36Z","timestamp":1771674276845,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.pupt.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T17:10:35Z","timestamp":1523639435000},"page":"82-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-0083","authenticated-orcid":false,"given":"G.","family":"Spoletini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Flint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3228-2327","authenticated-orcid":false,"given":"T.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Etherington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-2588","authenticated-orcid":false,"given":"N.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-9506","authenticated-orcid":false,"given":"I.","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2018.04.007_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.pupt.2018.04.007_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.04.007_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/mdr.2016.0048","article-title":"Increasing incidence of multidrug resistance among cystic fibrosis respiratory bacterial isolates","volume":"23","author":"Rutter","year":"2017","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.pupt.2018.04.007_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jcf.2013.04.014","article-title":"Drug induced complications; can we do more?","volume":"12","author":"Peckham","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2018.04.007_bib5","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/jac\/dkv221","article-title":"In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa","volume":"70","author":"Walsh","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pupt.2018.04.007_bib6","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.pupt.2018.04.007_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jcf.2006.08.003","article-title":"Fosfomycin\u2013investigation of a possible new route of administration of an old drug. A case study","volume":"6","author":"Cree","year":"2007","journal-title":"J. Cyst. Fibros."},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2018.04.007_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000222043","article-title":"Pharmacokinetic study of fosfomycin and its bioavailability","volume":"23","author":"Cad\u00f3rniga","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pupt.2018.04.007_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.20.3.393","article-title":"Fosfomycin kinetics after intravenous and oral administration to human volunteers","volume":"20","author":"Goto","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2018.04.007_bib10","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/BF01643430","article-title":"Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity","volume":"18","author":"Bergan","year":"1990","journal-title":"Infection"},{"key":"10.1016\/j.pupt.2018.04.007_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pupt.2018.04.007_bib12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections","volume":"34","author":"Roussos","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2018.04.007_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000222072","article-title":"Fosfomycin in treatment of respiratory bacterial infections","volume":"23","author":"Bonora","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pupt.2018.04.007_bib14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jac\/dkg187","article-title":"Target site penetration of fosfomycin in critically ill patients","volume":"51","author":"Joukhadar","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pupt.2018.04.007_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies","volume":"34","author":"Falagas","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.pupt.2018.04.007_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.pupt.2018.04.007_bib17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/cid\/ciu580","article-title":"Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant staphylococcus aureus: a multicenter clinical trial","volume":"59","author":"Del Rio","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pupt.2018.04.007_bib18","article-title":"Intravenous fosfomycin \u2013 back to the future. Systematic review and meta-analysis of the clinical literature","volume":"0","author":"Grabein","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.pupt.2018.04.007_bib19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/etm.2017.4046","article-title":"Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae","volume":"13","author":"Liao","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.pupt.2018.04.007_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02014882","article-title":"Fosfomycin in the treatment of cystic fibrosis","volume":"3","author":"Katznelson","year":"1984","journal-title":"Eur. J. Clin. Microbiol."},{"key":"10.1016\/j.pupt.2018.04.007_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1569-1993(02)00143-1","article-title":"Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis","volume":"2","author":"Mirakhur","year":"2003","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2018.04.007_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ijantimicag.2008.05.010","article-title":"Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis","volume":"32","author":"Faruqi","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.pupt.2018.04.007_bib23","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1569-1993(14)60180-6","article-title":"43 Experience with fosfomycin: clinical outcomes at an adult UK CF centre","volume":"13","author":"Wilson","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2018.04.007_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2007.06.006","article-title":"Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis","volume":"7","author":"Valenza","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2018.04.007_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.26.5.789","article-title":"Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa","volume":"26","author":"Takahashi","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2018.04.007_bib26","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/jac\/dkw115","article-title":"Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance","volume":"71","author":"Walsh","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pupt.2018.04.007_bib27","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1128\/AAC.39.5.1038","article-title":"Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm","volume":"39","author":"Kumon","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2018.04.007_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01709477","article-title":"In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa","volume":"16","author":"Tessier","year":"1997","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.pupt.2018.04.007_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcf.2014.03.005","article-title":"Daily serum creatinine monitoring promotes earlier detection of acute kidney injury in children and adolescents with cystic fibrosis","volume":"13","author":"Downes","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2018.04.007_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02329-16","article-title":"Nephrotoxicity in patients with or without cystic fibrosis treated with polymyxin B compared to colistin","volume":"61","author":"Crass","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455391730305X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455391730305X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T07:15:41Z","timestamp":1717312541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109455391730305X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":30,"alternative-id":["S109455391730305X"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2018.04.007","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}